<DOC>
	<DOCNO>NCT00842127</DOCNO>
	<brief_summary>The purpose study examine whether genetic polymorphism drug transporter associate side effect OROS-methylphenidate medication attention deficit/hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>Genetic Polymorphism OROS-Methylphenidate Treatment Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>20 30 % child attention deficit/hyperactivity disorder ( ADHD ) respond could tolerate methylphenidate treatment . Drug transporter multidrug resistant protein ( MDR ) play important role clearance psychotropic drug metabolites brain tissue . It suggest methylphenidate P-glycoprotein ( encode MDR1 gene ) substrate show inhibitory effect P-glycoprotein efflux function . Single nucleotide polymorphism ( SNP ) MDR1 gene analyze child adolescent OROS-methylphenidate treatment . The hypothesis MDR1 ( ABCB1 ) polymorphism associate side effect OROS-methylphenidate .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>ADHD Must able swallow capsule Pervasive developmental disorder Mental retardation Psychotic disorder Bipolar disorder Suicidality Neurological disorder Concurrent psychiatric treatment</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Methylphenidate</keyword>
	<keyword>ADHD</keyword>
	<keyword>Multidrug resistance ( MDR ) polymorphism</keyword>
	<keyword>OROS methylphenidate</keyword>
</DOC>